Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma
NCT ID: NCT04341740
Last Updated: 2023-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2020-07-22
2021-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participation in the research study will last approximately 60 days which includes time to determine if the patient is eligible to participate in the study, perform the research procedures and follow-up with the patient following the research procedures to determine if they are experiencing any side effects. Participation will end approximately 30 days following the bone marrow collection.
The bone marrow and blood samples will be collected from all patients in both cohorts only at a single time point, after they have been enrolled on the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal Cell Carcinoma or Urothelial Carcinoma Patients
Patients in both cohorts (RCC or UC) will undergo bone marrow aspiration under conscious sedation to withdraw 60 mL bone marrow aspirate and 75 ml of peripheral blood sample.
Bone Marrow Aspirate
bone marrow aspiration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bone Marrow Aspirate
bone marrow aspiration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically-confirmed, locally advanced unresectable or metastatic RCC (cohort A) or UC (cohort B).
* ECOG performance status of ≤1
* Adequate bone marrow function:
* Platelet count ≥ 100 × 10\^9/L
* ANC ≥ 1.0 ×10\^9/L
* Lymphocyte count ≥ 0.5 ×10\^9/L
* Willingness to undergo bone marrow aspiration (BMA)
Exclusion Criteria
* Prior radiation to the pelvic region
* Use of systemic corticosteroids within 28 days of BMA
* History of another primary malignancy that has been diagnosed or required therapy within the past 2 years (except completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site).
* Presence of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. If the autoimmune disease has been treated, it must be stable clinically. (Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is not considered an exclusion criterion.)
* Pregnant females as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy, obtained within 21 days of BMA
* Infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of BMA
* Known diagnosis of HIV or CMV infection or active viral hepatitis
* Administration of hematopoietic growth factor support within 14 days before bone marrow aspiration
* Chemotherapy administration within 28 days of BMA
* Unwilling or unable to comply with the protocol
* Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's opinion, could affect the safety of the subject.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
WindMIL Therapeutics
INDUSTRY
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abhishek Tripathi, MD
Role: PRINCIPAL_INVESTIGATOR
University of Oklahoma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OI-SCC-WINDMIL-001
Identifier Type: -
Identifier Source: org_study_id